ROBERT D. BRANDSTETTER, M.D.; VINCENT A. GRAZIANO, M.D.; MARCIA J. WADE, M.D.; STUART D. SAAL, M.D.
This content is PDF only. Please click on the PDF icon to access.
Carcinoembryonic antigen was first described in 1965 by Gold and Freedman (1). They defined an antigen detected by heterologous antisera in extracts from colonic adenocarcinoma and the digestive-tract organs of human embryos and fetuses. The initial finding of elevated carcinoembryonic antigen levels in 97% of patients with colonic cancer suggested that it was an early sensitive tumor marker (2). Later studies showed a better correlation between elevation and metastatic disease than with early stages of colonic cancer (3), and elevated levels were subsequently reported in carcinoma of the breast, lung, prostate, and lymphoid tissue (4-6).
The nonspecificity of carcinoembryonic antigen
BRANDSTETTER RD, GRAZIANO VA, WADE MJ, et al. Carcinoembryonic Antigen Elevation in Renal Failure. Ann Intern Med. 1979;91:867–868. doi: 10.7326/0003-4819-91-6-867
Download citation file:
Published: Ann Intern Med. 1979;91(6):867-868.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use